Q-omics provides the consensus-scored SLC26A10 profile across patient tissues and cancer cell-line models. SLC26A10 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC26A10 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SLC26A10 RNA expression shows 18,737 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where SLC26A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC26A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC26A10 survival associations across molecular data types. SLC26A10 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC26A10 RNA expression–survival associations across cancer types. High SLC26A10 expression shows unfavorable associations in ACC, UVM, KIRC, MESO and THCA, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC26A10 RNA expression.
This table summarizes SLC26A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC26A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC26A10 shows lower tumor expression in BRCA, STAD, KICH and BLCA and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher SLC26A10 RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .003).
This table shows molecular features associated with SLC26A10 in patient tissues and cancer cell lines. In patient samples, SLC26A10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC26A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and OVARY.
